HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions
about
Antigen-specific immunotherapy of cervical and ovarian cancerCross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic VaccinesLow NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions.Whole-Genome Analysis of Human Papillomavirus Types 16, 18, and 58 Isolated from Cervical Precancer and Cancer Samples in Chinese Women.Enhancement of tumor-specific T cell-mediated immunity in dendritic cell-based vaccines by Mycobacterium tuberculosis heat shock protein X.A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers.Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses.A comprehensive review on host genetic susceptibility to human papillomavirus infection and progression to cervical cancer.Therapeutic Vaccine Strategies against Human Papillomavirus.Prevalence of the NKG2D Thr72Ala polymorphism in patients with cervical carcinoma.Absence of γ-chain in keratinocytes alters chemokine secretion resulting in reduced immune cell recruitment.The immune response to papillomavirus during infection persistence and regression.HPV Vaccines: today and in the Future.HLA-DRB1 Class II antigen level alleles are associated with persistent HPV infection in Mexican women; a pilot study.A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells.Fighting Viral Infections and Virus-Driven Tumors with Cytotoxic CD4+ T Cells.Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer.Anal intraepithelial neoplasia and squamous cell carcinoma in HIV-infected adults.Natural history of high-grade cervical intraepithelial neoplasia: a review of prognostic biomarkers.Targeting Persistent Human Papillomavirus Infection.Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines.Identification of promiscuous HPV16-derived T helper cell epitopes for therapeutic HPV vaccine design.CD4+ T cells against human papillomavirus-18 E7 in patients with high-grade cervical lesions associate with the absence of the virus in the cervix.Cell-mediated immune response to human papillomavirus 16 E7 peptide pools in patients with cervical neoplasia.Cervical cancer-associated promoter polymorphism affects akna expression levels.
P2860
Q27488697-66C4829D-D832-41C5-AE33-234AAFFDD34CQ28085724-E651B9B2-B7D8-4B7A-A7AC-27029AEC4EC6Q33468660-E6D16280-CDE7-4E67-BEF2-80CAA1565927Q33670688-0269133E-FADC-4FA8-9E83-B3206C34C282Q33927138-DC3DF86B-7ED4-4EFA-AE70-E6C6A8661E88Q34121681-63DCDB12-EF97-42CB-8051-602445E98273Q35049821-1CBC26CD-D247-405E-91A2-27966ED105B6Q35749285-75C0E636-547E-4B8F-8A55-3F23E911ACB8Q35826752-1401B703-6160-493E-9143-1C678A6DD76DQ36174293-8192A0C7-A143-4997-A366-069730B6B482Q36410789-0124512C-4A54-45F7-87F3-13A0B9D92318Q36540399-630DD5BA-CB22-4A79-8224-0555DAB3E2C1Q36976268-9BFEB0BF-2050-465E-8D66-751C3F901D67Q37153746-867EFC30-7F1C-4206-9D9C-B996DE5459B4Q37434590-308BA159-08D9-42A9-969A-C6363AE52B3AQ37667998-B620631D-867F-4031-94FC-63F3CDD0ACFAQ38089937-08DA4D74-4F10-4B3D-BBF5-547BAA4A329AQ38134426-E2374E2E-37FF-4A58-AAF3-6885D18D23BEQ38363737-492C0A28-4FA4-43F1-AD44-40F20A8EFDF6Q40078375-FE03C0F2-0439-49E6-9E3A-47E9BE149D29Q42155977-4C074AC0-2E23-481A-8A1B-CA27666E3076Q42218961-CB9E3ADF-5BF2-454D-AE8D-71EF6182C765Q45375334-9E26EBA9-87D3-4B02-8A30-DF8AD944F7E1Q51008590-CFF96745-FAA7-4FAC-BF2E-AB0E25E9F66AQ53749377-4A24CFD9-F209-450D-9D41-4CB44EB8BC59
P2860
HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
HLA-DQB1*02-restricted HPV-16 ...... uamous intraepithelial lesions
@ast
HLA-DQB1*02-restricted HPV-16 ...... uamous intraepithelial lesions
@en
type
label
HLA-DQB1*02-restricted HPV-16 ...... uamous intraepithelial lesions
@ast
HLA-DQB1*02-restricted HPV-16 ...... uamous intraepithelial lesions
@en
prefLabel
HLA-DQB1*02-restricted HPV-16 ...... uamous intraepithelial lesions
@ast
HLA-DQB1*02-restricted HPV-16 ...... uamous intraepithelial lesions
@en
P2093
P2860
P1476
HLA-DQB1*02-restricted HPV-16 ...... uamous intraepithelial lesions
@en
P2093
Chien-Fu Hung
Cornelia Trimble
Drew Pardoll
Richard Roden
Shiwen Peng
P2860
P304
P356
10.1158/1078-0432.CCR-06-2916
P407
P577
2007-04-01T00:00:00Z